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Abstract
Background: The appropriate use of generic preference-based measures determines the accuracy of disease assessment
and further decision on healthcare policy using quality adjusted life years. The discriminative capacity of different
instruments would differ across disease groups. Our study was to examine the difference in utility scores for COPD patients
measured by EQ-5D and SF-6D and to assist the choice of a proper instrument in this disease group.
Methods: Differences of mean utility scores of EQ-5D and SF-6D in groups defined by socio-demographic characteristics,
comorbidities, health service utilisation and severity of illness were tested using Mann-Whitney test, t-test, Kruskal-Wallis
test, Pearson’s correlation coefficient and ANOVA, as appropriate. The discriminative properties of the two instruments were
compared against indicators of quality of life using receiver operating characteristic curves. The statistical significance of the
area under the curves (AUC) was tested by ANOVA and F-statistics used to compare the efficiency with which each
instrument discriminated between disease severity groups.
Results: Mean utility scores of EQ-5D and SF-6D were 0.644 and 0.629 respectively in the 154 subjects included in the
analysis. EQ-5D scores were significantly higher than SF-6D in groups less severe and these differences corresponded to a
minimally important difference of greater than 0.03 (p,0.001). EQ-5D and SF-6D scores were strongly correlated across the
whole sample (r = 0.677, p,0.001) and in pre-defined groups (r.0.5 and p,0.05 for all correlation coefficients). AUCs were
above 0.5 against the indicators of health-related quality of life for both instruments. F-ratios suggested SF-6D was more
efficient in discriminating cases of different disease severity than EQ-5D.
Conclusions: Both EQ-5D and SF-6D appeared to be valid preference-based measures in Chinese COPD patients. SF-6D was
more efficient in detecting differences among subgroups with differing health status. EQ-5D and SF-6D measured different
things and might not be used interchangeably in COPD patients.
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Background
There is an increasing need to express effectiveness of
interventions in terms of quality-adjusted life years (QALYs) in
health economic evaluations. The QALY accounts for both length
of life and health-related quality of life (HRQoL) in a single
outcome measure. Preference-based measures of health are
designed to construct QALYs. They consist of two parts, one a
standardized descriptive system for people to describe their own
health state, the other an algorithm for assigning values to each
state. The algorithm is usually based on valuations from a general
population sample of adults which are derived using techniques
such as standard gamble (SG) or time trade off (TTO). Preference-
based measures score health states on a scale of 0 to 1 equivalent to
death and full health respectively [1].
There are several preference-based measures including the EQ-
5D [2], the 15D [3], Health utility index (HUI) [4], Quality of
Well-Being (QWB) [5] and most recent of all, the SF-6D [6]. The
EQ-5D is currently the most popular preference-based instrument,
used in about half of published studies [7]. It is a two part
instrument, with the first part describing problems in five
dimensions with three response levels for each. The second part
consists of a vertical visual analogue scale (VAS) with zero at the
bottom referring to the worst health state and 100 at the top
referring to the best health state. The participant pointed to the
level on the scale indicating their overall health on the day of the
interview. The five dimensions (mobility, self-care, usual activities,
pain/discomfort, anxiety/depression) each with three levels (no
problems, some problems, extreme problems) can thus define 243
(35) different health states [1]. Using the TTO technique, country
specific scoring algorithms have been developed for the EQ-5D in
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UK [8], Norway [9], and Japan [10]. The EQ-5D has been
translated into Chinese and used in China, Taiwan, Hong Kong,
Singapore and Malaysia [11]. The SF-6D, which is increasingly
used, was developed from the SF-36 [6]. Six dimensions (physical
functioning, role limitation, social functioning, pain, mental
health, vitality) were retained from the original SF-36, each with
4 to 6 levels and it can define 18 000 (6*6*5*5*5*4) different health
states. Using the standard gamble (SG) technique, a scoring
algorithm for the SF-6D was developed for the UK [6,12].
The EQ-5D and the SF-6D differ from one another in terms of
their valuation techniques, classification systems, dimensions and
items covered. There is therefore a possibility that they will
generate a different utility score for a specific health state. Several
studies have directly compared these two instruments in different
populations, and these generally show disparities in the utility
scores derived from the EQ-5D and the SF-6D [12–20]. The EQ-
5D tends to generate higher scores than the SF-6D in healthy
population or patients with mild conditions and vice versa in less
healthy populations or among patients with severe conditions
[13,17,19], leading to variation in the estimation of utility scores
and QALYs which could influence decisions taken on resource use
[21–23].
Harper et al showed that the SF-36 performed better in
detecting changes in HRQoL in patients with mild COPD in
outpatient settings than did the EQ-5D [24]. However, no study to
our knowledge has directly compared the performance of EQ-5D
and SF-6D for those with more severe stages of COPD. In order to
assist clinicians and researchers in choosing the most appropriate
instrument for discriminative and evaluative purposes we per-
formed a head-to-head comparison of the EQ-5D and the SF-6D
in a group of severe and very severe COPD patients. COPD was
chosen because it is known to have a significant adverse impact on
HRQoL [25–30]. The burden of the disease in terms of morbidity
and mortality is projected to increase in the next few decades in
East Asia and elsewhere making the ability to determine QALY
loss important [31,32], thus a precise measure is required in
estimate of QALYs and to better inform the healthcare policy
using quality-adjusted life years as outcome.
Methods
Sample and data collection
The study was conducted between September 2010 and May
2011 in a respiratory specialist out-patient clinic (SOPC) in a
public hospital (Princess Margret Hospital) in Hong Kong. All the
patients with COPD who regularly attended the SOPC were
screened by their medical records for the study. Patients who had
severe (post-bronchodilator FEV1 30–49% of predicted) or very
severe (post-bronchodilator FEV1% , 30% of predicted) COPD
according to the Global Obstructive Lung Disease (GOLD)
standard [33] during the past one year were included. Those who
had significant comorbidities which prevented their participation,
such as dementia or Parkinson’s disease, who did not have a
pulmonary function test result within the past one year or who did
not speak Cantonese were excluded and all the eligible patients
were invited to participate in the study. From 166 patients
approached, 2 patients were incommunicable (one was deaf and
one was unable to speak), 5 refused to participate, and 159 (95.8%)
provided written consent to participate and were interviewed by
trained interviewers. Five of the interviewed participants were
excluded from the analysis because their post FEV1 was 50% of
predicted which classified their severity stage as moderate. Thus,
154 patients were included in the final data analysis.
Subjects completed the respiratory disease specific Saint
George’s Respiratory Questionnaire (SGRQ), the SF-6D and the
EQ-5D. They also answered questions on socio-demographic
information (sex, age, education, housing type and income), self-
rated health status (‘‘Compared with past 12 months, what do you
think about your present health condition? Better, The same,
Worse’’) and life style information (e.g. smoking). The SF-6D and
the EQ-5D were asked in a random sequence to avoid possible
order effects. Utilization of health services (hospital admissions in
the past 12 month) and presence of comorbidities (i.e. other than
COPD, whether being diagnosed with hypertension, heart
diseases, pneumonia, diabetes, asthma, rheumatoid arthritis, liver
disease, cancers and other chronic diseases) were extracted directly
from patients’ medical records by one research nurse in the
SOPC.
The study was approved by the Kowloon West Cluster Clinical
Research Ethics Committee, Hong Kong. All participants
provided written informed consent to participate in this study.
HRQoL Measures
The Cantonese Chinese version of the EQ-5D and the Chinese
(Hong Kong) SF-6D questionnaire were used to measure the
Health Related Quality of Life (HRQoL) of the sample patients
[34]. Because a Hong Kong specific scoring algorithm was not
available for the EQ-5D, the UK one was used for which direct
valuations of 43 health states had been elicited from a sample of
the general population using TTO and the theoretic utility scores
ranged from 20.59 to 1 [35].
Direct valuations for 196 health states from the SF-6D HK had
been valued by a representative sample of the Hong Kong
population (n= 582) using SG and the theoretic utility scores
ranged from 0.315 to 1 [36]. This algorithm was employed in the
present study to generate utility scores but, in order to compare
with scores from the EQ-5D, the UK scoring algorithm for the SF-
6D [6] was also used.
The Hong Kong Chinese version of the St. George’s
Respiratory Questionnaire (SGRQ) was included as a measure
of disease specific quality of life. The SGRQ contains 76 weighted
responses divided into three sections covering distress due to
respiratory symptoms, disturbance of physical activity and overall
impact on daily life and well-being. A total score from 0 to 100 is
summed from weighted positive responses and a higher score
indicates worse HRQoL [37]. The Chinese version of the SGRQ
had already been validated in patients with COPD in Hong Kong
[38] and, although the weights applied to the responses have not
been developed in Hong Kong, they appear to be similar in
different countries and in different languages [39] so cultural or
linguistic factors may not greatly affect responses to this
questionnaire [40].
Statistical analysis
Utility scores for the EQ-5D and the SF-6D were both
estimated using UK-derived scoring algorithms for direct
comparison and a SGRQ total summary score was calculated.
Possible ceiling and floor effects, represented by the proportion of
participants with the best and worst theoretical scores respectively,
were identified. Correlation between the SGRQ scores and EQ-
5D or SF-6D or EQ-VAS scores were tested using Pearson’s
correlation coefficient.
The EQ-5D, SF-6D and SGRQ mean scores were compared
for different groups defined by levels of socio-demographic
variables, comorbidities or health service utilisation. Where the
relevant variable had two levels, this between-group comparison
used the Mann-Whitney test for the EQ-5D or t-test for the SF-6D
EQ5D and SF6D in COPD
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and SGRQ. Where the relevant variable had three or more levels,
this comparison used the Kruskal-Wallis test for the EQ-5D scores
or the one way analysis of variance (ANOVA) for SF-6D scores
and SGRQ. Association between the EQ-5D and SF-6D mean
scores of each level of each variable was identified using Pearson’s
correlation coefficient and statistical significance of the difference
was assessed by paired-sample t-test. A minimally important
difference (MID) was defined as a difference of at least 0.03
between the EQ-5D and the SF-6D mean scores [20,41,42].
To determine whether the mean utility scores of the EQ-5D and
SF-6D followed the pattern that less severe patients had higher
scores on the EQ-5D and more severe patients scored higher on
SF-6D, the correlations between EQ-5D and SGRQ as well as
SF-6D and SGRQ were tested by simple linear regression. The
difference between the SF-6D and EQ-5D scores was regressed to
SGRQ scores to further explore whether the two utility scores vary
with severity differently. SGRQ was used as an external indicator
of disease severity in COPD patients.
The discriminative properties of the EQ-5D and SF-6D were
compared using receiver operating characteristic (ROC) curves.
The area under the ROC curve (AUC) indicates the possibility of
correctly discriminating between dichotomized groups (e.g.
‘‘severe’’ vs. ‘‘very severe’’). In our analysis, the performance of
the EQ-5D and SF-6D was evaluated against a couple of
commonly used external indicators of HRQoL: the EQ-VAS
scores and the SGRQ summary scores. These indicators were
dichotomized using different cut-off points. EQ-VAS scores and
SGRQ scores was grouped according to the percentiles of the
Table 1. Characteristics of the study sample (n = 154).
Severe COPD Very severe COPD Total
n % n % n %
Number of patients 100 65.0 54 35.0 154 100.0
Age (yrs, mean ±, sd)" 74.867.9 69.467.4 72.968.1
Gender (male) 98 98 54 100 152 98.7
COPD duration
(yrs, mean 6 sd) 6.864.2 7.964.8 7.264.4
Lung function: post FEV1% (mean ± sd)
" 38.165.7 22.665.1 32.769.2
Education
No/pre-primary 30 30.0 7 13.0 37 24.0
Primary 49 49.0 31 57.4 80 52.0
Secondary 20 20.0 15 27.8 35 22.7
Post-secondary 1 1.0 1 1.9 2 1.3
Monthly family income (HK$)
No income 73 73.0 33 61.1 106 68.8
,$10,000 26 26.0 20 37.0 46 29.9
.$10,000 1 1.0 1 1.9 2 1.3
Housing
Public or aided 76 76.0 47 87.0 123 79.9
Private or Old people’s home 24 24.0 7 13.0 31 20.1
Smoking`
Current smoker 16 16.0 3 5.6 19 12.3
Ex-smoker 83 83.0 47 87.0 130 84.4
Never smoker 1 1.0 4 7.4 5 3.3
ComorbidityP
No 35 35.0 15 27.8 50 32.5
Yes 65 65.0 39 72.2 104 67.5
Hospital admission in the past 12 month
No 33 33.0 10 18.5 43 27.9
Yes 67 67.0 44 81.5 111 72.1
Perceived health (compared to previous year)
Better 11 11.0 4 7.4 15 9.7
Same 18 18.0 7 13.0 25 16.2
Worse 71 71.0 43 79.6 114 74.0
PPresence with any following disease: hypertension, heart diseases, pneumonia, diabetes, asthma, rheumatoid arthritis, liver disease, cancers and other chronic diseases.
"p,0.001, significance was tested by t-test.
`p,0.05, significance was tested by chi-square test.
Note: COPD = Chronic Obstructive Pulmonary Disease.
doi:10.1371/journal.pone.0112389.t001
EQ5D and SF6D in COPD
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score distribution. The statistical significance of the AUC (F-
statistic) was tested by ANOVA for each instrument. F-statistics for
the SF-6D and EQ-5D were compared by dividing the F-statistic
of the SF-6D by that of the EQ-5D (F-ratio). A value greater than
one indicates that the SF-6D is more efficient than the EQ-5D at
detecting differences in quality of life. The significance level was
set as p,0.05 and all analyses were performed using STATA
(StataCorp. 2013. Stata Statistical Software: Release 13. College
Station, TX: StataCorp LP).
Results
Almost all the patients were male (98.7%), 65.0% were in the
severe COPD stage and, on average, had been diagnosed with
COPD for 7 years (SD 4.4) (Table 1). More than 80% were ex-
smokers while 12% were current smokers. Fewer than 30% had
secondary education or higher and 68.8% had no family income
while 67.5% of them were with comorbid conditions and 72.1%
had been admitted to hospital at least once in the past 12 months.
Around three-quarters of the group (74.0%) reported their health
to be worse compared with the previous year.
The mean scores on the EQ-5D and the SF-6D (UK) were
0.644 and 0.629 respectively. The distribution of EQ-5D, SF-6D
(UK and HK) and SGRQ scores were generally skewed,
particularly noticeable for the EQ-5D (Figure 1). The EQ-5D
showed a ceiling effect with 22.1% of patients reporting the highest
possible scores. No ceiling effect was observed in the SF-6D or
SGRQ. Both EQ-5D and SF-6D scores were negatively associated
with SGRQ since high scores indicated good HRQoL on EQ-5D
and SF-6D but poor HRQoL on the SGRQ. Correlation was
Figure 1. Distribution of EQ-5D, SF-6D (UK), SF-6D (HK) and SGRQ scores.
doi:10.1371/journal.pone.0112389.g001
Table 2. Distribution of EQ-5D, SF-6D (UK & HK), EQ-VAS and SGRQ scores in the sample subjects and their correlations with SGRQ.
Measures Theoretical range Observed range Mean ± sd Ceiling effect (%) Floor effect (%) Pearson correlation"
EQ-5D 20.590, 0.919 20.184, 0.919 0.64460.306 34 (22.1) 0 20.583
SF-6D (HK) 0.315, 1 0.315, 0.950 0.59160.147 0 2 (1.3) 20.745
SF-6D (UK) 0.296, 1 0.296, 0.960 0.62960.133 0 1 (0.6) 20.728
EQ-VAS 0, 100 0, 100 55.28620.42 4 (2.6) 5 (3.2) 20.437
SGRQ 100, 0 91.62, 16.84 61.07618.53 0 0 –
"EQ-5D, SF-6D and EQ-VAS correlated with SGRQ; p,0.001 for all Pearson’s correlation coefficient.
Note: SGRQ = Saint George’s Respiratory Questionnaire.
doi:10.1371/journal.pone.0112389.t002
EQ5D and SF6D in COPD
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higher between SF-6D (HK and UK) and SGRQ (r =20.745 and
20.728, p,0.001) than between EQ-5D and SGRQ (r =20.583,
p,0.001) (Table 2).
The EQ-5D and SF-6D mean scores were strongly correlated
across the whole sample (r = 0.677, p,0.001) and a scatter plot
further showed this when regressing EQ-5D to SF-6D (the
coefficient ß = 0.30, p,0.001, and the constant = 0.44, p,
0.001) (Figure 2). In subgroups defined by disease severity, socio-
demographic characteristics and utilization of health services, the
EQ-5D and SF-6D mean scores were strongly correlated as well
(Table 3). Both measures were sensitive to differences within
subgroups in disease severity, hospital admission and presence or
not of comorbidities and differences detected were statistically
significant.
Direct comparison of the EQ-5D and SF-6D showed that in the
less severe cases indicated by lower SGRQ scores, the EQ-5D
scores were higher than SF-6D (Figure 3 above). On the contrary,
the SF-6D scores were higher than EQ-5D in more severe cases
indicated by a higher SGRQ scores. There appeared a cross-over
of these two utility scores. The correlation between the difference
of the SF-6D and EQ-5D (SF-6D – EQ-5D) and SGRQ score was
positive (b=0.004, p,0.001) (Figure 3 below). The difference in
most cases (88.3%) were greater than the MID of 0.03.
The AUC showed the discriminative ability of the EQ-5D and
SF-6D to distinguish between very severe and severe COPD as
defined by EQ-VAS and SGRQ summary scores. Against both
indicators of HRQoL, the AUC scores for both instruments were
above 0.5 suggesting that they can detect the difference between
severe and very severe cases (Table 4). For most of the
comparisons, the SF-6D generated a larger AUC than the EQ-
5D. Most of the F-ratios was greater than 1 which showed SF-6D
to be more efficient in discriminating cases of differed disease
severity than EQ-5D.
Discussion
It is important to compare the available preference-based
measures of health because the choice of instrument can greatly
influence the eventual decision-making based on the results.
Different instruments can have differing sensitivity to disease-
related quality of life impacts and can display ceiling or floor
effects in some populations. This comparative study of the EQ-5D
and the SF-6D in people with severe or very severe COPD
confirmed the ceiling effect of the EQ-5D, that is, a substantial
group of subjects scored the highest possible score, even though all
had COPD classed as severe by lung function tests. This ceiling
effect of the EQ-5D has been noted in other studies [12,13,16].
Both of the instruments demonstrated a moderate capacity to
distinguish between previously defined groups in terms of disease
severity as assessed by lung function, by whether they had a recent
hospital admission and by whether they had any comorbidities.
Neither instrument was found to be clearly superior. When
compared with the SGRQ, the SF-6D showed stronger correlation
coefficients and generated a larger AUC than EQ-5D implying
that SF-6D may be better at reflecting the health status of those
with severe COPD.
Both the EQ-5D and the SF-6D discriminated well between
pre-defined subgroups with mainly significant differences between
mean scores for groups defined by disease severity, hospital
admissions and presence of comorbidities. Thus there is evidence
of construct validity for each measure in identifying HRQoL of
people with severe and very severe COPD. The EQ-5D and SF-
6D were strongly positively correlated (Pearson’s correlation
coefficient .0.5 and statistically significant) throughout the entire
sample and pre-defined subgroups. Despite this, the difference in
mean scores on the two measures in pre-defined subgroups often
constituted a MID.
Even though the EQ-5D and SF-6D generated similar mean
scores in our sample, the distributions were very different. The SF-
6D utility scores followed a relative normal distribution, unlike the
EQ-5D scores which were negatively skewed with a clustering at
the maximum score of one. It was clear from the analysis that the
EQ-5D appeared with larger ceiling effect (22.1%) compared with
the SF-6D (UK and HK) in our sample. Previous studies in
populations with chronic diseases have also reported ceiling effects
for the EQ-5D [43–45]. It suggested that the EQ-5D, in which
Figure 2. Scatter plot of EQ-5D and SF-6D.
doi:10.1371/journal.pone.0112389.g002
EQ5D and SF6D in COPD
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22.1% of our sample patients scored the highest possible score,
may not be as efficient as SF-6D in reflecting the disease severity.
Further direct comparison of the EQ-5D and the SF-6D scores
against disease severity indicated by SGRQ scores also confirmed
this. The relationship observed between the SF-6D and SGRQ
differed from that between the EQ-5D and SGRQ, where the SF-
6D scored higher in more severe cases and the EQ-5D scored
higher in less severe cases. This may be due to valuation
techniques, which is TTO for the EQ-5D, as well as scaling
properties. Others have found that SG generally produces higher
values than TTO for the same condition [35,46] but TTO usually
gives higher values than SG for milder health states [47]. This
suggests that there might be a ‘‘cross-over’’ point for TTO and SG
scores along the axis of illness severity and hence, also, for EQ-5D
and SF-6D values. We did indeed see this crossover point in our
study.
Moreover, consistent with other studies [19,21,45], the SF-6D
was more efficient in detecting HRQoL differences between
subgroups than the EQ-5D with the SF-6D generating larger
AUCs and the F-ratio of SF-6D to EQ-5D being greater than 1 in
most cases in our study. Specifically, Harper et al had already
shown that SF-36 was better than EQ5D in detecting minor
changes in HRQoL for those with mild COPD in outpatient
settings [24] and our study adds evidence that in severe and very
severe stages of COPD, the EQ-5D and the SF-6D show different
discriminative capacities with SF-6D being more efficient in
detecting changes in HRQoL. However, some studies have still
preferred to use the EQ-5D for chronic disease in clinic settings
and for comparing HRQoL pre and post-intervention [43]. Stel et
Figure 3. Scatter plots of SF-6D vs. SGRQ, EQ-5D vs. SGRQ (above) and difference (SF-6D – EQ-5D) vs. SGRQ (below).
doi:10.1371/journal.pone.0112389.g003
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al found that the EQ-5D had a substantially lower percentage of
missing data than the SF-6D both at baseline and post-
intervention assessments when assessing the impact of different
surgical interventions on patients with coronary heart disease. Our
study did not find such a difference in completeness. Thus along
with Harper et al [24], the SF-6D would be a more precise
measurement in estimate of QALYs in patients with COPD than
the EQ-5D. It is evident that the EQ-5D and the SF-6D yield
different utility values and measured different things in COPD
patients. There two instruments might not be used interchange-
ably, so a careful choice needs to be made. It is therefore
important for clinical and health technology assessment authorities
to choose the most appropriate measurement to better inform the
healthcare policy using QALYs as outcome. More comparative
studies would be useful.
Strengths and limitations
To our knowledge, our study was the first head to head
comparison of the SF-6D and the EQ-5D among Chinese subjects
with a severe chronic disease. Classifying health status using
SGRQ and EQ-VAS scores could capture the underlying disease
severity and provide reliable and validated external measures of
HRQoL. Existing clinical conditions and related health care
utilization data were extracted directly from medical records
which minimized errors and bias in recall.
However, there were several potential limitations in our study.
Firstly, the UK-derived scoring algorithms were used for
comparing the EQ-5D and the SF-6D since there was no local
algorithm available for the EQ-5D. This may fail to reflect the true
preference in a Chinese population. Secondly, our sample was
mainly male (98%) which may limit the external validity of our
results. However, evidence on any gender difference in HRQoL is
not conclusive with many studies showed non-significant differ-
ences [25,27,29,48,49]. A local study did not find any difference in
the HRQoL of males and females with COPD who were attending
community health centers (unpublished data). Finally, the cross-
sectional nature of this study renders it unable to test the ability of
the instruments to detect changes in HRQoL.
Conclusions
Both the EQ-5D and the SF-6D appeared to be valid and
discriminative preference-based measures of health in Chinese
patients with severe and very severe COPD. Our study added
evidence that the SF-6D was more efficient in detecting differences
among subgroups with differing disease severity of COPD. The
EQ-5D and the SF-6D measured different things and might not be
used interchangeably in COPD patients. Further research would
be needed to determine other psychometric properties of the EQ-
5D and the SF-6D such as responsiveness to assess ability to detect
longitudinal changes.
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